Antipsychotic Dose Reduction After Psychosis: What the RADAR Trial Changed

Key answer

A plain-English review of the RADAR randomized trial, its finding of more relapse without better social functioning at two years, and what it does and does not mean. The central safety principle is: Does supported gradual antipsychotic reduction improve social functioning compared with maintenance treatment? [1–2]

A safe interpretation starts with the exact medication or intervention, the reason it is being used, the formulation, treatment duration, other medicines, current symptoms, and the risks of both continuing and changing treatment. The article therefore explains decision factors and safety boundaries rather than prescribing a fixed schedule.

At a glance

Evidence basis and uncertainty

This article prioritizes regulator-hosted product information, current clinical guidance, systematic reviews, randomized trials, and carefully labeled observational or mechanistic evidence. The references below are used according to their design and limitations [1–2]. Absence of a detected signal is not rewritten as absence of risk, and a population average is not presented as an individual prediction.

Working definitions

Why RADAR mattered

Antipsychotic adverse effects are important, and many people reasonably ask whether lower doses improve cognition, motivation, metabolic health, or quality of life. RADAR tested a structured reduction strategy rather than relying only on observational comparisons.

What the trial found

At two years, the reduction group did not show a measurable advantage in the primary social-functioning outcome and experienced more relapses than the maintenance group. This is a clinically important counterweight to mechanistic arguments that slower or hyperbolic reduction will necessarily protect against relapse.

What population and intervention matter

Results apply most directly to people similar to the trial participants and to the strategy actually tested. Diagnosis, illness duration, baseline stability, dose, support, reduction depth, and follow-up influence generalizability. A result at two years does not answer every longer-term or first-episode question.

Withdrawal-associated relapse versus illness relapse

Some researchers argue that receptor adaptation and withdrawal can contribute to early relapse after reduction. RADAR does not fully resolve mechanism. Clinically, the immediate priority is recognizing deterioration and restoring safety rather than assigning a single cause from timing alone.

What should change in practice

Reduction after psychosis should be a shared, specialist-led decision with explicit relapse risk, early warning signs, family or support involvement when appropriate, rapid access to care, and a plan for sleep and substance use. A receptor-occupancy curve is not enough to guarantee safety.

When urgent medical assessment may be needed

    Seek urgent local medical assessment when any of the following applies. This list is intentionally conservative and is not a diagnostic checklist:

    - Emerging paranoia, hallucinations, disorganization, mania, or severe insomnia

• Immediate self-harm or violence risk

• Loss of follow-up or inability to access rapid psychiatric care

• Dose reduction is being pursued despite active psychosis or severe instability

    Emergency pathways and telephone numbers vary by country. A tracking application or educational article cannot rule out an emergency.

Questions to take to the prescriber

• What is the current indication and treatment goal?
• Which alternative explanations for the symptoms need assessment?
• What is the exact medication, formulation, timing, and most recent change?
• Which outcome should be monitored before another change is considered?
• What are the urgent warning signs and the fastest route back to the clinical team?

Frequently asked questions

Did RADAR prove maintenance is best forever?

No. It found no social-function advantage and more relapse for the tested reduction strategy over two years. Longer-term and subgroup questions remain.

Did participants taper too quickly?

That is debated, but post hoc explanations do not erase the randomized outcome. Alternative strategies require direct comparative evidence.

Can adverse effects still justify reduction?

Yes. The expected benefit must be balanced against relapse risk with close specialist monitoring.

Is relapse after reduction always withdrawal?

No. Withdrawal, dopamine adaptation, stress, substance use, and recurrence of illness may overlap. Timing alone cannot decide.

Regional and formulation note

Guidelines, labels, formulations, and care pathways vary by country. Verify the exact product label, manufacturer, strength, release system, and local clinical pathway before use. A tablet or capsule instruction that is correct for one product may be wrong for another.

References

1. Moncrieff J, et al. Antipsychotic dose reduction and discontinuation versus maintenance treatment (RADAR): randomized trial. 2023. Evidence type: Randomized clinical trial. Use in this article: At two years, gradual reduction increased relapse and did not improve the primary social-functioning outcome in the studied population.

2. Horowitz MA, et al. A method for tapering antipsychotic treatment that may minimize relapse. 2021. Evidence type: Mechanistic proposal and narrative review. Use in this article: Provides a receptor-based rationale; comparative clinical-outcome evidence is still limited.